The molecular and cellular processes that maintain a physiological balance in blood coagulation and inflammation are acutely altered in sepsis. The resulting coagulopathy and inflammation cause disability and death among a large proportion of sepsis patients throughout the developed and undeveloped world. Millions of patients are diagnosed with sepsis each year, with the associated expenditure of tens of billions of dollars in health care costs. Still, sepsis is increasing in incidence with the prevalence and virulence of infectious pathogens. Lack of sufficient knowledge of the pathophysiology of sepsis including host responses has primarily contributed to the paucity of current treatments. This program project integrates the expertise of multiple biomedical scientists and clinicians whom have recently made potentially transformative and translational discoveries of host responses in sepsis that remodel glycoproteins of the blood and vasculature. This remodeling alters glycan linkages on blood glycoproteins and diminishes heparin sulfate proteoglycan tethering to the vascular wall, resulting in changes to the half-lives, abundance, and functions of blood and vascular glycoproteins with a profound impact on the coagulopathy, inflammation, and lethality of sepsis. Further discoveries that this program project team are poised to make are expected to achieve significant advances in the mechanistic understanding of the life-threatening changes to host blood and vascular systems during sepsis. The program is integrated by a central hypothesis proposing that Protein glycosylation and glycoprotein remodeling modulate the coagulopathy and inflammation of sepsis. The research projects are highly synergistic with interdisciplinary and state of the art technologies that span four core facilities to support three research projects that all address the central hypothesis of the program. The overall objective is to identify and investigate blood and vascular glycoprotein remodeling mechanisms and their multiple effects on coagulopathy, inflammation, and the outcomes of Gram-negative and Gram-positive bacterial sepsis in mice and compared with the underlying Systemic Inflammatory Response Syndrome (SIRS). The program will also incorporate analyses of blood samples from human patients diagnosed with sepsis or SIRS.
The research aims encompass investigations of coagulation, tissue coagulopathy, inflammation markers, glycan linkages, serology, pathogen burden, and comparative proteomic analyses of blood samples. Recent findings demonstrate that conserved glycoprotein homeostatic mechanisms differentially modulate the pathogenesis and outcomes of sepsis caused by distinct pathogens, supporting the emerging view that sepsis is not a singular disease process.
The specific aims of this program project are further derived from extensive preliminary data that supports the proposed studies. The combined results of this program will generate insights into host responses and mechanisms that modulate the coagulopathy and inflammation of sepsis, and will generate important information needed to develop more effective diagnostic and therapeutic approaches.

Public Health Relevance

The coagulopathy and inflammation of sepsis are a major cause of human disability and death with millions of people affected in the U.S. each year. Death as an outcome still averages 30%, underscoring the incomplete knowledge of sepsis and the need for breakthroughs in biomedical research of this long-standing problem. This research proposal will focus on newly discovered and previously understudied molecular mechanisms operating in the host that modulate the coagulopathy and inflammation of this deadly syndrome in order to transform the understanding and improve the treatment of sepsis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL131474-04
Application #
9685689
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Sarkar, Rita
Project Start
2016-07-15
Project End
2021-04-30
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sanford Burnham Prebys Medical Discovery Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Yang, Won Ho; Heithoff, Douglas M; Aziz, Peter V et al. (2018) Accelerated Aging and Clearance of Host Anti-inflammatory Enzymes by Discrete Pathogens Fuels Sepsis. Cell Host Microbe 24:500-513.e5
Qiu, Hong; Shi, Songshan; Yue, Jingwen et al. (2018) A mutant-cell library for systematic analysis of heparan sulfate structure-function relationships. Nat Methods 15:889-899
Barnes, Lucien; Heithoff, Douglas M; Mahan, Scott P et al. (2018) Smartphone-based pathogen diagnosis in urinary sepsis patients. EBioMedicine 36:73-82
Yamasaki, Tokiwa; Deki-Arima, Norie; Kaneko, Asahito et al. (2017) Age-dependent motor dysfunction due to neuron-specific disruption of stress-activated protein kinase MKK7. Sci Rep 7:7348
van Wijk, Xander M; Döhrmann, Simon; Hallström, Björn M et al. (2017) Whole-Genome Sequencing of Invasion-Resistant Cells Identifies Laminin ?2 as a Host Factor for Bacterial Invasion. MBio 8:
Ersoy, Selvi C; Heithoff, Douglas M; Barnes 5th, Lucien et al. (2017) Correcting a Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility Testing. EBioMedicine 20:173-181
Yang, Won Ho; Heithoff, Douglas M; Aziz, Peter V et al. (2017) Recurrent infection progressively disables host protection against intestinal inflammation. Science 358:
Li, Yun; Fu, Jianxin; Ling, Yun et al. (2017) Sialylation on O-glycans protects platelets from clearance by liver Kupffer cells. Proc Natl Acad Sci U S A 114:8360-8365
van Wijk, Xander M; Thijssen, Victor L; Lawrence, Roger et al. (2013) Interfering with UDP-GlcNAc metabolism and heparan sulfate expression using a sugar analogue reduces angiogenesis. ACS Chem Biol 8:2331-8